LOEWI
Key Facts
| Invested since | 2020 |
| Based in | Bavaria |
About the company
LOEWI GmbH is a scientific spin-off of the TU München with the mission to make personalized health and nutrition available to everyone by combining science and technology. LOEWI’s patented personalization concept analyzes health relevant data of customers and patients, makes the analysis available via LOEWI’s Health Profile (Medical Software Class I), and creates personalized nutrient recommendations and therapies using a sophisticated recommendation algorithm, which are 100% tailored to the personal needs of each customer and patient.
Do you want to
know more about this company?
LOEWI in the news
Zum Artikel
LOEWI GmbH receives seed financing to make personalized health and nutrition available for everyone
More startups from Life Sciences
CustomSurg, founded in 2021, is a Spin-Off from ETH Zurich and Harvard University. The company is developing software-as-a-medical-device (SaMD) solutions for the optimal selection and placement of orthopaedic implants in …
To the complete profileof CustomSurg
NovaPump GmbH is developing and realising a leading solution for a novel right ventricular assist device (RVAD) with clear USPs (the only percutaneous device with pulsatile support). NovaPump’s catheter-based heart …
To the complete profileof NovaPump
Refined Laser Systems GmbH, based in Münster, Germany, was founded in 2019 as a spin-off from University of Münster by Max Brinkmann, Tim Hellwig and Christoph Seidenstücker. The company’s core …
To the complete profileof Refined Laser Systems
Exit
m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated …
To the complete profileof m2p-labs
mediaire develops AI-powered diagnostic solutions for MRI imaging, focusing on the seamless integration of AI into clinical workflows to enhance radiologists’ efficiency and diagnostic accuracy. The company’s AI solutions, including …
To the complete profileof mediaire
InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, …
To the complete profileof InCephalo
Exit
Humedics markets a system for bedside and instantaneous measurement of liver function. Patented device, consumables and a diagnostic drug allow an optimal market offering.
To the complete profileof Humedics
Sedivention is developing a medical device for a new therapy of obesity. The Blizzard cryocatheter freezes the nerve branches, that transmit an increased, inadequate feeling of hunger to the brain …
To the complete profileof Sedivention
Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.
To the complete profileof Cryotherapeutics
Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular …
To the complete profileof HepaRegeniX
NAVAN, Inc. (NAVAN) is an early-stage private biotechnology company developing a novel, proprietary NanoStraw platform to enable the next generation of cell and gene therapies. A non-viral physical delivery technology, …
To the complete profileof Navan
Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.
To the complete profileof ALGIAX